PTC Therapeutics Inc. has continued its string of Big Pharma tie-ups with its latest deal with Roche. The two companies announced Nov. 28 that they have entered into another venture, the first between the Big Pharma and the biotech since their deal in 2009. Roche is just one of PTC’s large pharmaceutical partners, which also include Merck & Co. Inc. and AstraZeneca PLC.
PTC, based in South Plainfield, N.J., will receive $30 million upfront and has the potential to earn $460 million in development and commercial milestones, as well as double-digit royalties. In exchange, Roche will have an exclusive worldwide license to PTC’s spinal muscular atrophy (SMA) program, including three pre-clinical assets and potential back-up compounds
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?